Journal Club

This is a preview of subscription content, access via your institution.


  1. 1.

    Horner ME, Alikhan A, Tintle S, Tortorelli S, Davis DMR, Hand JL. Cutaneous porphyrias part I: epidemiology, pathogenesis, presentation, diagnosis, and histopahhology. Int J Dermatol 2013; 52: 1464–80.

    Article  Google Scholar 

  2. 2.

    Christiansen AL, Brock A, Bygum A, Rasmussen LM, Jepsen P. Increased mortality in patients with porphyria cutanea tarda: a nationwide cohort study. J Am Acad Dermatol 2020; 83:817–23.

    Article  Google Scholar 

  3. 3.

    Frew JW, Marzano AV, Wolk K, et al. A systematic review of promising therapeutic targets in hidradenitis suppurativa: a critical evaluation of mechanistic and clinical relevance. J Invest Dermatol 2020; S0022–202X(20): 31826–31.

    Google Scholar 

  4. 4.

    Savage KT, Flood KS, Porter ML, Kimball AB. TNF-α inhibitors in the treatment of hidradenitis suppurativa. Ther Adv Chronic Dis 2019; 10:2040622319851640.

    CAS  Article  Google Scholar 

  5. 5.

    Tzanetakou V, Kanni T, Giatrakou S, et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial. JAMA Dermatol 2016; 152: 52–9.

    Article  Google Scholar 

  6. 6.

    Kanni T, Argyropoulou M, Spyridopoulos T, et al. MABp1 targeting IL-1α for moderate to severe hidradenitis suppurativa not eligible for adalimumab: a randomized study. J Invest Dermatol 2018; 138: 795–801.

    CAS  Article  Google Scholar 

  7. 7.

    Casseres RG, Prussick L, Zancanaro P, et al. Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial. J Am Acad Dermatol 2020; 82: 1524–6.

    CAS  Article  Google Scholar 

  8. 8.

    Gulliver WP, Jemec GBE, Baker KA. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2012; 26:911–4.

    CAS  Article  Google Scholar 

  9. 9.

    Berman HS, Villa NM, Shi VY, Hsiao JL. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn’s disease. J Dermatol Treat 2019: 1–3.

  10. 10.

    Patel N, McKenzie SA, Harview CL, et al. Isotretinoin in the treatment of hidradenitis suppurativa: a retrospective study. J Dermatol Treat 2019: 1–3.

  11. 11.

    Giamarellos-Bourboulis EJ, Argyropoulou M, Kanni T, et al. Clinical efficacy of complement C5a inhibition by IFX-1 in hidradenitis suppurativa: an open-label single-arm trial in patients not eligible for adalimumab. Br J Dermatol 2020; 183: 176–8.

    CAS  Article  Google Scholar 

  12. 12.

    Golbari NM, Porter ML, Kimball AB. Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2019; 80: 114–9.

    CAS  Article  Google Scholar 

  13. 13.

    Verdolini R, Clayton N, Smith A, Alwash N, Mannello B. Metformin for the treatment of hidradenitis suppurativa: a little help along the way. J Eur Acad Dermatol Venereol 2013; 27: 1101–8.

    CAS  Article  Google Scholar 

  14. 14.

    Savage KT, Santillan MR, Flood KS, Charrow A, Porter ML, Kimball AB. Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients. JAAD Case Rep 2020;6:99–102.

    Article  Google Scholar 

  15. 15.

    Elman SA, Joyce C, Braudis K, et al. Creation and validation of classification criteria for discoid lupus erythematosus. JAMA Dermatol 2020; 156:901–6.

    Article  Google Scholar 

  16. 16.

    Fabbri P, Cardinali C, Giomi B, Caproni M. Cutaneous lupus erythematosus: diagnosis and management. Am J Clin Dermatol 2003;4:449–65.

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Verena Frings.

Additional information


Financial support: none. Conflicts of interest: none.

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lesort, C., Grän, F., Machado, Á. et al. Journal Club. Eur J Dermatol 30, 759–760 (2020).

Download citation